Last summer, the world had a major scare with one of the deadliest diseases known to mankind, Ebola, when a few of the poorest countries in Africa (and altogether the world) were attacked with the virus, taking thousands of lives on the way as it spread dangerously; now, a year later, the Ebola vaccine 2015 might be the answer millions have been hoping for.
While the Ebola vaccine 2015 proves 100 percent effective in the latest trials, Nasdaq reports that the U.S. Food and Drug Administration (FDA) has recently approved an emergency use authorization (EUA) for its diagnosis test for the disease, which uses fingerstick and venous whole blood.
According to The Guardian, though, it's the Ebola vaccine 2015 taking up all the headlines, after more than 7,600 people in Guinea have received the new vaccine since April 2014, and the results are downright spectacular, as not one of those people suffered from this disease in spite of being in communities where there are cases of Ebola.
Staggeringly enough, it's not only that the Ebola vaccine 2015 is showing 100 percent effectiveness, but in fact it's been well tolerated by those who have taken it, and the side effects have been minimal, a rarity in vaccines that contain live virus.
The results of the Ebola vaccine 2015 trial were published on The Lancet under the study title "Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomized trial."
Io9 reports that a Canadian company has been developing this vaccine, rVSV-ZEBOV, since 2011, and it was tested between 90 clusters of the disease in thousands of people, all of which have continued to go completely unscathed by the passing of this deadly virus.
Of course, this is only a major trial and it doesn't necessarily mean the end of the disease, but the Ebola vaccine 2015 is a huge light of hope after one of the most catastrophic epidemics in recent times.
